Tiny clots, big problem<\/h2>\n\n\n\n
Microthrombi are microscopic blood clots. They form inside very small blood vessels, the kind that help carry oxygen and nutrients to brain cells.<\/p>\n\n\n\n
Read More: Are you a lark or a night owl? Science says the Mediterranean chrono-diet has 6 menus to unlock your metabolism based on your body clock<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nWhy would that matter in a disease known for memory loss? If blood cannot move smoothly, nearby neurons may get less fuel. Over time, that shortage could make fragile brain tissue even more vulnerable.<\/p>\n\n\n\n
What scientists found<\/h2>\n\n\n\n
The new work detected microthrombi<\/a> in living mice bred to model Alzheimer\u2019s disease. <\/p>\n\n\n\nThe project brought together the Spanish National Center for Cardiovascular Research, the Spanish National Research Council, and the Fundaci\u00f3n Jim\u00e9nez D\u00edaz Health Research Institute, with additional partners in Madrid.<\/p>\n\n\n\n
The finding matters because these clots had largely been invisible during life. They were usually studied after death, when doctors and scientists examined brain tissue. In practical terms, that meant the problem could be seen only after the chance to intervene had passed.<\/p>\n\n\n\n![\"Illustration](\"https:\/\/okdiario.com\/metabolic\/en\/wp-content\/uploads\/2026\/07\/brain-microthrombi-alzheimers-blood-vessels.jpg\" "\\"\\"")
An illustration showing microscopic blood clots, or microthrombi, inside a blood vessel. New research suggests these tiny clots may disrupt blood flow in the brain, contributing to Alzheimer’s disease progression and offering a potential new target for diagnosis and treatment.<\/figcaption><\/figure>\n\n\n\nHow the scan works<\/h2>\n\n\n\n
The team used positron emission tomography, or PET, a type of scan already used in hospitals. PET works by sending a small signal from a tracer, which is a substance designed to attach to a specific target in the body.<\/p>\n\n\n\n
\n\n\nRead More: A copper-based drug cleared toxic Alzheimer’s proteins and restored memory in the lab, and the breakthrough it points is curious<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nIn this case, the targets were parts of clots, including fibrin and platelets. Fibrin is a protein that helps blood clot, and platelets are tiny blood cells that gather when a clot forms. When more of these clot markers were present, the scanner picked up a stronger signal.<\/p>\n\n\n\n
A blood-flow angle<\/h2>\n\n\n\n
For decades, Alzheimer\u2019s research has focused heavily on amyloid and tau<\/a>. Amyloid forms sticky plaques outside brain cells, while tau forms tangled strands inside them.<\/p>\n\n\n\nBut the brain is not only a collection of nerve cells. It is also packed with blood vessels, and even small changes in circulation can matter. Think of a neighborhood during a traffic jam. The buildings are still there, but getting around slows down and stress levels intensify.<\/p>\n\n\n\n
A possible biomarker<\/h2>\n\n\n\n
A biomarker is a measurable sign of disease or wellness. In Alzheimer\u2019s care today, doctors may use brain scans, spinal fluid tests, and blood tests to look for the biology of the disease, especially amyloid and tau. <\/p>\n\n\n\n
The Alzheimer\u2019s Association\u2019s 2024 criteria<\/a> also put more weight on biological signs, not only memory symptoms.<\/p>\n\n\n\nIf microthrombi can be detected safely in people, they might become another biomarker. That could help doctors see which patients have a stronger blood-clotting component to their disease. It could also help explain why two people with similar memory symptoms<\/a> do not always decline at the same pace.<\/p>\n\n\n\nTreatment questions remain<\/h2>\n\n\n\n
This is where the news gets interesting, but also where caution matters. The research points toward a future in which some patients might be considered for therapies that protect the brain<\/a>\u2019s tiny blood vessels.<\/p>\n\n\n\nThat does not mean people with Alzheimer\u2019s should start taking blood thinners<\/a> on their own. Anticoagulants can cause bleeding, and the study was not a human treatment trial. The safer takeaway is that scientists may now have a better way to identify who should be studied next.<\/p>\n\n\n\nEarlier clues fit the picture<\/h2>\n\n\n\n
The vascular idea did not appear out of nowhere. A 2019 JACC study<\/a> reported that long-term dabigatran treatment delayed Alzheimer-like disease processes in a mouse model, adding earlier support to the idea that clotting pathways may matter in this illness.<\/p>\n\n\n\n\n\n\nRead More: It’s not the omega-3 fish oil you swallow daily to stave off Alzheimer’s that works, and a new clinical trial just revealed the truth<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nStill, mouse studies are not the same as patient care. Mice help researchers test mechanisms in a controlled setting, but human brains, bodies, medications, and risks are more complicated. That\u2019s why the next steps will need careful clinical research.<\/p>\n\n\n\n
Why this changes the story<\/h2>\n\n\n\n
Marta Cort\u00e9s Canteli, who led work that included Carlos Cer\u00f3n, Marta Casquero-Veiga, and Nicol\u00e1s Lamanna-Rama, said the finding “opens the door to new diagnostic and therapeutic targets.” <\/p>\n\n\n\n
That is a careful phrase, not a promise of a cure. It means the work may help researchers look beyond a single explanation of Alzheimer\u2019s<\/a> and study the disease as a mix of nerve damage, protein buildup, inflammation, and blood-vessel trouble.<\/p>\n\n\n\nAt the end of the day, the study gives scientists a better roadmap. Not the fastest route to a definitive cure. The official study has been published in Alzheimer\u2019s & Dementia<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Alzheimer\u2019s is often described as a disease of memory, but the new finding points to something more basic, blood flow. … <\/p>\n
The project brought together the Spanish National Center for Cardiovascular Research, the Spanish National Research Council, and the Fundaci\u00f3n Jim\u00e9nez D\u00edaz Health Research Institute, with additional partners in Madrid.<\/p>\n\n\n\n
The finding matters because these clots had largely been invisible during life. They were usually studied after death, when doctors and scientists examined brain tissue. In practical terms, that meant the problem could be seen only after the chance to intervene had passed.<\/p>\n\n\n\n The team used positron emission tomography, or PET, a type of scan already used in hospitals. PET works by sending a small signal from a tracer, which is a substance designed to attach to a specific target in the body.<\/p>\n\n\n\n In this case, the targets were parts of clots, including fibrin and platelets. Fibrin is a protein that helps blood clot, and platelets are tiny blood cells that gather when a clot forms. When more of these clot markers were present, the scanner picked up a stronger signal.<\/p>\n\n\n\n For decades, Alzheimer\u2019s research has focused heavily on amyloid and tau<\/a>. Amyloid forms sticky plaques outside brain cells, while tau forms tangled strands inside them.<\/p>\n\n\n\n But the brain is not only a collection of nerve cells. It is also packed with blood vessels, and even small changes in circulation can matter. Think of a neighborhood during a traffic jam. The buildings are still there, but getting around slows down and stress levels intensify.<\/p>\n\n\n\n A biomarker is a measurable sign of disease or wellness. In Alzheimer\u2019s care today, doctors may use brain scans, spinal fluid tests, and blood tests to look for the biology of the disease, especially amyloid and tau. <\/p>\n\n\n\n The Alzheimer\u2019s Association\u2019s 2024 criteria<\/a> also put more weight on biological signs, not only memory symptoms.<\/p>\n\n\n\n If microthrombi can be detected safely in people, they might become another biomarker. That could help doctors see which patients have a stronger blood-clotting component to their disease. It could also help explain why two people with similar memory symptoms<\/a> do not always decline at the same pace.<\/p>\n\n\n\n This is where the news gets interesting, but also where caution matters. The research points toward a future in which some patients might be considered for therapies that protect the brain<\/a>\u2019s tiny blood vessels.<\/p>\n\n\n\n That does not mean people with Alzheimer\u2019s should start taking blood thinners<\/a> on their own. Anticoagulants can cause bleeding, and the study was not a human treatment trial. The safer takeaway is that scientists may now have a better way to identify who should be studied next.<\/p>\n\n\n\n The vascular idea did not appear out of nowhere. A 2019 JACC study<\/a> reported that long-term dabigatran treatment delayed Alzheimer-like disease processes in a mouse model, adding earlier support to the idea that clotting pathways may matter in this illness.<\/p>\n\n\n\n Still, mouse studies are not the same as patient care. Mice help researchers test mechanisms in a controlled setting, but human brains, bodies, medications, and risks are more complicated. That\u2019s why the next steps will need careful clinical research.<\/p>\n\n\n\n Marta Cort\u00e9s Canteli, who led work that included Carlos Cer\u00f3n, Marta Casquero-Veiga, and Nicol\u00e1s Lamanna-Rama, said the finding “opens the door to new diagnostic and therapeutic targets.” <\/p>\n\n\n\n That is a careful phrase, not a promise of a cure. It means the work may help researchers look beyond a single explanation of Alzheimer\u2019s<\/a> and study the disease as a mix of nerve damage, protein buildup, inflammation, and blood-vessel trouble.<\/p>\n\n\n\n At the end of the day, the study gives scientists a better roadmap. Not the fastest route to a definitive cure. The official study has been published in Alzheimer\u2019s & Dementia<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Alzheimer\u2019s is often described as a disease of memory, but the new finding points to something more basic, blood flow. … <\/p>\n
An illustration showing microscopic blood clots, or microthrombi, inside a blood vessel. New research suggests these tiny clots may disrupt blood flow in the brain, contributing to Alzheimer’s disease progression and offering a potential new target for diagnosis and treatment.<\/figcaption><\/figure>\n\n\n\nHow the scan works<\/h2>\n\n\n\n
Read More: A copper-based drug cleared toxic Alzheimer’s proteins and restored memory in the lab, and the breakthrough it points is curious<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
A blood-flow angle<\/h2>\n\n\n\n
A possible biomarker<\/h2>\n\n\n\n
Treatment questions remain<\/h2>\n\n\n\n
Earlier clues fit the picture<\/h2>\n\n\n\n
Read More: It’s not the omega-3 fish oil you swallow daily to stave off Alzheimer’s that works, and a new clinical trial just revealed the truth<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
Why this changes the story<\/h2>\n\n\n\n